SCHEMBL1579439

SCHEMBL1579439

NC(=O)c1cc(-c2ccccc2)sc1Nc1cncnc1

nearest known ligand 0.78

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 13/20 0.78
▸ JAK3 P52333 3/20 0.78
▸ IKBKB O14920 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1579845 0.88 JAK2 (1.00) JAK2JAK3IKBKB
SCHEMBL1579949 0.86 JAK2 (1.00) JAK2JAK3IKBKB
SCHEMBL1890249 0.86 JAK2 (1.00) JAK2JAK3IKBKB
SCHEMBL3512122 0.77 JAK2 (1.00) JAK2JAK3IKBKB
SCHEMBL14011075 0.77 JAK2 (0.77) JAK2JAK3IKBKB
SCHEMBL1385889 0.76 JAK2 (1.00) JAK2JAK3IKBKB
SCHEMBL3513503 0.76 JAK2 (1.00) JAK2JAK3IKBKB
SCHEMBL3509957 0.76 JAK2 (0.76) JAK2JAK3IKBKB
SCHEMBL3509993 0.76 JAK2 (1.00) JAK2JAK3IKBKB
SCHEMBL3507945 0.76 JAK2 (1.00) JAK2JAK3IKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420695-B2 Inhibitors of janus kinases MERCK SHARP & DOHME CORP. (US) 2013-04-16 — — US claimed
JP-2011527680-A — — 2011-11-04 — — JP claimed
US-20110112081-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-05-12 — — US claimed
EP-2310384-A1 INHIBITORS OF JANUS KINASES Merck Sharp & Dohme Corp. (US) 2011-04-20 — — EP claimed
WO-2010005841-A1 INHIBITORS OF JANUS KINASES MERCK & CO., INC. (US) 2010-01-14 — — WO claimed
US-8420695-B2 Inhibitors of janus kinases MERCK SHARP & DOHME CORP. (US) 2013-04-16 — — US disclosed
US-8420695-B2 Inhibitors of janus kinases MERCK SHARP & DOHME CORP. (US) 2013-04-16 — — US disclosed
US-8420695-B2 Inhibitors of janus kinases MERCK SHARP & DOHME CORP. (US) 2013-04-16 — — US disclosed
US-20110112081-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-05-12 — — US disclosed
US-20110112081-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-05-12 — — US disclosed
US-20110112081-A1 INHIBITORS OF JANUS KINASES MERCK SHARP & DOHME LLC 2011-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110112081-A1 INHIBITORS OF JANUS KINASES JAK2, JAK3, JAK1 JAK2 1/4885JAK3 2/4885IKBKB 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback